ARQT (Arcutis Biotherapeutics) Total Assets : $348.9 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Arcutis Biotherapeutics Total Assets?

Arcutis Biotherapeutics's Total Assets for the quarter that ended in Dec. 2024 was $348.9 Mil.

During the past 12 months, Arcutis Biotherapeutics's average Total Assets Growth Rate was 74.00% per year. During the past 3 years, the average Total Assets Growth Rate was 79.00% per year. During the past 5 years, the average Total Assets Growth Rate was 80.70% per year.

During the past 8 years, Arcutis Biotherapeutics's highest 3-Year average Total Assets Growth Rate was 411.10%. The lowest was 71.30%. And the median was 90.40%.

Total Assets is connected with ROA %. Arcutis Biotherapeutics's annualized ROA % for the quarter that ended in Dec. 2024 was -10.98%. Total Assets is also linked to Revenue through Asset Turnover. Arcutis Biotherapeutics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.18.

Arcutis Biotherapeutics Total Assets Historical Data

The historical data trend for Arcutis Biotherapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcutis Biotherapeutics Total Assets Chart

Arcutis Biotherapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

298.27

408.15

449.27

341.37

348.89

Arcutis Biotherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															341.37	478.54	444.76	437.35	348.89

Arcutis Biotherapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Arcutis Biotherapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	157.541	+	191.348
	=	348.9

Arcutis Biotherapeutics's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	157.541	+	191.348
	=	348.9

Arcutis Biotherapeutics (NAS:ARQT) Total Assets Explanation

Total Assets is connected with ROA %.

Arcutis Biotherapeutics's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-43.152	/	( (437.354	+	348.889)	/ 2 )
	=	-43.152	/	393.1215
	=	-10.98 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Arcutis Biotherapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	71.36	/	( (437.354	+	348.889)	/ 2 )
=	71.36	/	393.1215
=	0.18

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Arcutis Biotherapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Arcutis Biotherapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Arcutis Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcutis Biotherapeutics Inc (NAS:ARQT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361

Website

https://www.arcutis.com

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Executives

Todd Franklin Watanabe	director, officer: President and CEO	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Patrick Burnett	officer: See Remarks	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Howard G. Welgus	director	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Masaru Matsuda	officer: SVP and General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Larry Todd Edwards	officer: Chief Commercial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Terrie Curran	director	C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Matthew Richard Moore	officer: SVP and Chief Business Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patrick J Heron	director, 10 percent owner	550 HAMILTON AVE., SUITE 100, PALO ALTO CA 94301
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Scott L Burrows	officer: Chief Financial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 3027 TOWNSGATE ROAD, SUITE 300, WESTLAKE VILLAGE CA 91361
Patricia A. Turney	officer: Senior VP, Manufacturing	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
David W Osborne	officer: Chief Technical Officer
Kenneth A. Lock	officer: Chief Commercial Officer	C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD, SUITE 110, WESTLAKE VILLAGE CA 91361
Neha Krishnamohan	director	12707 HIGH BLUFF DRIVE, SAN DIEGO CA 92130
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022